Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to “Hold” Rating by StockNews.com

StockNews.com cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research note released on Wednesday.

Several other equities analysts have also weighed in on SRPT. Guggenheim increased their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Raymond James reissued an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. UBS Group increased their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Barclays decreased their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $114.23 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 1-year low of $78.67 and a 1-year high of $173.25. The stock has a market capitalization of $10.91 billion, a P/E ratio of 91.38 and a beta of 0.81. The business has a 50-day moving average price of $122.00 and a two-hundred day moving average price of $131.53.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter worth about $31,000. New Covenant Trust Company N.A. acquired a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $32,000. Sunbelt Securities Inc. raised its holdings in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank boosted its position in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. Finally, Nkcfo LLC bought a new position in Sarepta Therapeutics in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.